Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

Next-Generation Karyotyping Outperforms Conventional Cytogenetics for Prognostication of AML

Compared with conventional cytogenetic analysis (CCA), next generation sequencing (NGS)–based karyotyping offered greater insight into the prognosis of patients with intensively treated acute myeloid...

Universal CAR-T Platform Shows Promising Efficacy in Relapsed/Refractory AML

Initial findings from a proof-of-concept study led by Martin Wermke, MD, from the Technical University of Dresden in Germany, suggest that UniCAR, a universal,...

Cellular Therapies Hold Promise in Myeloid Malignancies

There is hope that these therapies will improve outcomes, but development is still in early stages.  A recent spate of approvals of targeted treatments, such...

Daunorubicin and Cytarabine Combination Approved for Pediatric Secondary AML

The U.S. Food and Drug Administration (FDA) has approved a revised label for liposomal daunorubicin and cytarabine, CPX 351, to include a new indication...

Is Pretransplant Disease Reduction Necessary in MDS and AML?

For patients with myelodysplastic syndromes (MDS) or low-blast secondary acute myeloid leukemia (AML), allogeneic hematopoietic cell transplantation (AHCT) is the only potentially curative treatment...

Kronos Bio Announces Phase III Trial of Entospletinib in NPM1-Mutated AML

Kronos Bio says it has reached an agreement with the U.S. Food and Drug Administration (FDA) to launch a phase III clinical trial evaluating...

IND Application Cleared for VOR33 in CD33+ Acute Myeloid Leukemia

The FDA cleared Vor Biopharma’s IND application for its hematopoietic cell therapy VOR33. This decision allows the company to initiate a phase I/IIa clinical...
WIB_icon

Leukemia Antigen–Specific Donor-Derived T Cells Enhance Graft-Versus-Leukemia Effects in Post-Transplant AML/MDS

For patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) whose disease relapses following a hematopoietic cell transplantation (HCT), unselected donor lymphocytes typically...
WIB_icon

Researchers Develop a Validated Pediatric Disease Risk Index for AML and ALL

A pediatric disease risk index (DRI) reported in Blood was capable of stratifying children with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL)...

The Future of Chronic Graft-Versus-Host Disease

An Update From the 3rd NIH Chronic GVHD Consensus Conference In this edition, Steven Pavletic, MD, and Kirk Schultz, MD, report on the progress and...
Advertisement

Current Issue

May 2021 Volume 7 Issue 6

This issue provides an update on gene therapies in hematology, demystifies RNA sequencing, and more.

Block title